Lyon, France - MaaT Pharma (EURONEXT: MAAT the 'Company'), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux and an increase of EUR50,000 to the resources allocated to the contract, in accordance with the provisions of article 4 of AMF decision no. 2021-01 of June 22, 2021.
Under the liquidity contract entered into between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2024: 26,929 shares
EUR 17,089.40
Number of executions on buy side on semester: 933
Number of executions on sell side on semester: 1,014
Traded volume on buy side on semester: 28,959 shares for EUR 237,891.32
Traded volume on sell side on semester: 26,266 shares for EUR 220,168.07 As a reminder: the following resources appeared on the last half year statement on December 31, 2023 on the liquidity account: 24,236 shares
EUR 34,107.60
Number of executions on buy side on semester: 627
Number of executions on sell side on semester: 368
Traded volume on buy side on semester: 18,328 shares for EUR 122,340.49
Traded volume on sell side on semester: 9,576 shares for EUR 64,693.03
The following resources appeared on the liquidity account when the activity started: 0 shares
EUR 200,000.00
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris.
Contact:
Tel: 04 28 29 14 00
Email: contact@maat-pharma.com
MAAT PHARMA 
